Physician profile
Stephen Deal
NPI 1598783961
$944,904.13
in general payments reported to CMS, 2019-2025
36 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167K · 2020: $156K · 2021: $176K · 2022: $146K · 2023: $144K · 2024: $116K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $298K · Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $297,635.45 |
| Food and Beverage | $2,952.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $929,204.39 | 2019-2025 | Fusion |
| Cook Incorporated | $8,633.54 | 2025 | |
| Abbvie INC. | $2,092.55 | 2019-2024 | Skyrizi, Linzess, Viberzi |
| Vivus LLC | $553.21 | 2021-2024 | Qsymia, Pancreaze |
| Pfizer INC. | $541.18 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.09 | 2019-2024 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $436.01 | 2019-2024 | Entyvio, Eohilia |
| Celgene Corporation | $427.50 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $374.73 | 2019-2024 | Stelara, Simponi, Tremfya |
| Ironwood Pharmaceuticals, INC | $362.71 | 2020-2023 | Linzess |
| Qol Medical, LLC | $318.64 | 2019-2023 | Sucraid |
| Redhill Biopharma INC. | $146.72 | 2020-2023 | |
| 3-D Matrix, INC. | $144.11 | 2024 | |
| Ferring Pharmaceuticals INC. | $137.57 | 2019-2023 | Rebyota |
| Amgen INC. | $128.98 | 2020-2023 | Amjevita |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $106.39 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $90.47 | 2022-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $90.36 | 2022 | |
| Intra-Sana Laboratories | $84.91 | 2021-2022 | |
| Cook Medical LLC | $72.03 | 2021-2023 | Fusion Quattro |
| Gilead Sciences, INC. | $62.18 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $54.08 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $52.28 | 2022-2024 | Dupixent |
| Braintree Laboratories, INC. | $49.25 | 2023 | Sutab, Suflave |
| Lilly USA, LLC | $44.15 | 2024 | Omvoh |
| W. L. Gore & Associates, INC. | $31.37 | 2022-2023 | Gore Cardioform Septal Occluder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.12 | 2023 | Cyltezo |
| Organon LLC | $27.05 | 2024 | |
| Daiichi Sankyo INC. | $22.90 | 2023 | Injectafer |
| Fresenius Kabi USA, LLC | $18.03 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $17.80 | 2023 | Zeposia |
| Evoke Pharma, INC. | $16.10 | 2020 | |
| Allergan, INC. | $14.88 | 2020 | |
| Merck Sharp & Dohme LLC | $13.71 | 2022 | |
| Conmed Corporation | $12.71 | 2021 | |
| Shionogi INC | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Deal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.